Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD).Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220-450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received do...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Korean Association for the Study of Intestinal Diseases
2016
|
| _version_ | 1826283641408323584 |
|---|---|
| author | Wu, K Ran, Z Gao, X Chen, M Zhong, J Sheng, J Kamm, M Travis, S Wallace, K Mostafa, N Shapiro, M Li, Y Thakkar, R Robinson, A |
| author_facet | Wu, K Ran, Z Gao, X Chen, M Zhong, J Sheng, J Kamm, M Travis, S Wallace, K Mostafa, N Shapiro, M Li, Y Thakkar, R Robinson, A |
| author_sort | Wu, K |
| collection | OXFORD |
| description | This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD).Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220-450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg at weeks 4 and 6. An open-label extension period occurred from weeks 8-26; patients received 40 mg adalimumab every other week. Serum adalimumab concentration and change from baseline in fecal calprotectin (FC) were measured during the double-blind period. Clinical remission (CDAI <150), response (decrease in CDAI ≥70 points from baseline), and change from baseline in hs-CRP were assessed through week 26. Nonresponder imputation was used for missing categorical data and last observation carried forward for missing hs-CRP/FC values. No formal hypothesis was tested. Adverse events were monitored.Mean adalimumab serum concentrations during the induction phase were 13.9-18.1 µg/mL (160/80 mg group) and 7.5-9.5 µg/mL (80/40 mg group). During the double-blind period, higher remission/response rates and greater reductions from baseline in hs-CRP and FC were observed with adalimumab 160/80 mg compared to that with 80/40 mg. Adverse event rates were similar among all treatment groups.Adalimumab serum concentrations in Chinese patients with CD were comparable to those observed previously in Western and Japanese patients. Clinically meaningful remission rates and improvement in inflammatory markers were achieved with both dosing regimens; changes occurred rapidly with adalimumab 160/80 mg induction therapy. No new safety signals were reported. |
| first_indexed | 2024-03-07T01:01:56Z |
| format | Journal article |
| id | oxford-uuid:8a061575-aee5-4587-b991-7eac7c491127 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:01:56Z |
| publishDate | 2016 |
| publisher | Korean Association for the Study of Intestinal Diseases |
| record_format | dspace |
| spelling | oxford-uuid:8a061575-aee5-4587-b991-7eac7c4911272022-03-26T22:28:35ZAdalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's diseaseJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8a061575-aee5-4587-b991-7eac7c491127EnglishSymplectic Elements at OxfordKorean Association for the Study of Intestinal Diseases2016Wu, KRan, ZGao, XChen, MZhong, JSheng, JKamm, MTravis, SWallace, KMostafa, NShapiro, MLi, YThakkar, RRobinson, AThis was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD).Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220-450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg at weeks 4 and 6. An open-label extension period occurred from weeks 8-26; patients received 40 mg adalimumab every other week. Serum adalimumab concentration and change from baseline in fecal calprotectin (FC) were measured during the double-blind period. Clinical remission (CDAI <150), response (decrease in CDAI ≥70 points from baseline), and change from baseline in hs-CRP were assessed through week 26. Nonresponder imputation was used for missing categorical data and last observation carried forward for missing hs-CRP/FC values. No formal hypothesis was tested. Adverse events were monitored.Mean adalimumab serum concentrations during the induction phase were 13.9-18.1 µg/mL (160/80 mg group) and 7.5-9.5 µg/mL (80/40 mg group). During the double-blind period, higher remission/response rates and greater reductions from baseline in hs-CRP and FC were observed with adalimumab 160/80 mg compared to that with 80/40 mg. Adverse event rates were similar among all treatment groups.Adalimumab serum concentrations in Chinese patients with CD were comparable to those observed previously in Western and Japanese patients. Clinically meaningful remission rates and improvement in inflammatory markers were achieved with both dosing regimens; changes occurred rapidly with adalimumab 160/80 mg induction therapy. No new safety signals were reported. |
| spellingShingle | Wu, K Ran, Z Gao, X Chen, M Zhong, J Sheng, J Kamm, M Travis, S Wallace, K Mostafa, N Shapiro, M Li, Y Thakkar, R Robinson, A Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease |
| title | Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease |
| title_full | Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease |
| title_fullStr | Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease |
| title_full_unstemmed | Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease |
| title_short | Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease |
| title_sort | adalimumab induction and maintenance therapy achieve clinical remission and response in chinese patients with crohn s disease |
| work_keys_str_mv | AT wuk adalimumabinductionandmaintenancetherapyachieveclinicalremissionandresponseinchinesepatientswithcrohnsdisease AT ranz adalimumabinductionandmaintenancetherapyachieveclinicalremissionandresponseinchinesepatientswithcrohnsdisease AT gaox adalimumabinductionandmaintenancetherapyachieveclinicalremissionandresponseinchinesepatientswithcrohnsdisease AT chenm adalimumabinductionandmaintenancetherapyachieveclinicalremissionandresponseinchinesepatientswithcrohnsdisease AT zhongj adalimumabinductionandmaintenancetherapyachieveclinicalremissionandresponseinchinesepatientswithcrohnsdisease AT shengj adalimumabinductionandmaintenancetherapyachieveclinicalremissionandresponseinchinesepatientswithcrohnsdisease AT kammm adalimumabinductionandmaintenancetherapyachieveclinicalremissionandresponseinchinesepatientswithcrohnsdisease AT traviss adalimumabinductionandmaintenancetherapyachieveclinicalremissionandresponseinchinesepatientswithcrohnsdisease AT wallacek adalimumabinductionandmaintenancetherapyachieveclinicalremissionandresponseinchinesepatientswithcrohnsdisease AT mostafan adalimumabinductionandmaintenancetherapyachieveclinicalremissionandresponseinchinesepatientswithcrohnsdisease AT shapirom adalimumabinductionandmaintenancetherapyachieveclinicalremissionandresponseinchinesepatientswithcrohnsdisease AT liy adalimumabinductionandmaintenancetherapyachieveclinicalremissionandresponseinchinesepatientswithcrohnsdisease AT thakkarr adalimumabinductionandmaintenancetherapyachieveclinicalremissionandresponseinchinesepatientswithcrohnsdisease AT robinsona adalimumabinductionandmaintenancetherapyachieveclinicalremissionandresponseinchinesepatientswithcrohnsdisease |